Mizuho Reaffirms “Buy” Rating for Xeris Pharmaceuticals (NASDAQ:XERS)

Mizuho reissued their buy rating on shares of Xeris Pharmaceuticals (NASDAQ:XERS) in a research report released on Tuesday morning, AnalystRatings.com reports. Mizuho currently has a $27.00 target price on the stock.

“We applied a weighted average valuation methodology (DCF+EV/Sales) to derive our $27 PT. Our assumptions include: Launch of the glucagon rescue pen in the U.S. market in 4Q19, with unadjusted peak-sales of $454 mil in 2028 (current PoS: 90%).”,” Mizuho’s analyst wrote.

A number of other research firms have also weighed in on XERS. ValuEngine raised shares of Xeris Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday, August 20th. Royal Bank of Canada set a $18.00 price target on shares of Xeris Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, August 7th.

XERS opened at $10.37 on Tuesday. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.00 and a quick ratio of 6.00. The company’s 50-day moving average is $11.21 and its 200 day moving average is $10.75. Xeris Pharmaceuticals has a fifty-two week low of $6.85 and a fifty-two week high of $26.50. The firm has a market capitalization of $275.81 million, a P/E ratio of -2.08 and a beta of -0.40.

Xeris Pharmaceuticals (NASDAQ:XERS) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($1.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.34). Xeris Pharmaceuticals had a negative net margin of 4,876.50% and a negative return on equity of 107.65%. The firm had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.20 million. On average, equities research analysts expect that Xeris Pharmaceuticals will post -4.72 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of Montreal Can bought a new position in shares of Xeris Pharmaceuticals during the second quarter valued at about $26,000. Tower Research Capital LLC TRC purchased a new stake in Xeris Pharmaceuticals during the second quarter worth about $42,000. BNP Paribas Arbitrage SA purchased a new stake in Xeris Pharmaceuticals during the first quarter worth about $43,000. Marshall Wace North America L.P. purchased a new stake in Xeris Pharmaceuticals during the first quarter worth about $71,000. Finally, Susquehanna International Group LLP purchased a new stake in Xeris Pharmaceuticals during the second quarter worth about $118,000. 66.15% of the stock is currently owned by institutional investors.

About Xeris Pharmaceuticals

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

Read More: What is the formula for the cash asset ratio?

Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.